VERTEX PHARMACEUTICALS INC / MA (VRTX) Total liabilities 2016–2025
VERTEX PHARMACEUTICALS INC / MA (VRTX) total liabilities at each fiscal year-end, per SEC filings.
$7.0BFY2025 · since FY2016: $1.6B → $7.0B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $7.0B | +13.9% |
| FY2024 | $6.1B | +18.9% |
| FY2023 | $5.1B | +21.5% |
| FY2022 | $4.2B | +27.2% |
| FY2021 | $3.3B | +8.7% |
| FY2020 | $3.1B | +37.2% |
| FY2019 | $2.2B | +23.3% |
| FY2018 | $1.8B | +20.4% |
| FY2017 | $1.5B | -3.5% |
| FY2016 | $1.6B | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More VRTX financial trends
VRTX RevenueVRTX Net incomeVRTX Net marginVRTX Gross profitVRTX Gross marginVRTX Operating incomeVRTX Operating marginVRTX Operating cash flowVRTX Free cash flowVRTX Capital expendituresVRTX Return on equityVRTX Stock buybacksVRTX Dividends paidVRTX Total assetsVRTX Shareholders’ equityVRTX overview →